Integra Gross Profit Margin vs Total Cash From Operating Activities Analysis
IART Stock | USD 28.89 0.14 0.49% |
Integra LifeSciences financial indicator trend analysis is infinitely more than just investigating Integra LifeSciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Integra LifeSciences is a good investment. Please check the relationship between Integra LifeSciences Gross Profit Margin and its Total Cash From Operating Activities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Gross Profit Margin vs Total Cash From Operating Activities
Gross Profit Margin vs Total Cash From Operating Activities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Integra LifeSciences Gross Profit Margin account and Total Cash From Operating Activities. At this time, the significance of the direction appears to have no relationship.
The correlation between Integra LifeSciences' Gross Profit Margin and Total Cash From Operating Activities is 0.01. Overlapping area represents the amount of variation of Gross Profit Margin that can explain the historical movement of Total Cash From Operating Activities in the same time period over historical financial statements of Integra LifeSciences Holdings, assuming nothing else is changed. The correlation between historical values of Integra LifeSciences' Gross Profit Margin and Total Cash From Operating Activities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit Margin of Integra LifeSciences Holdings are associated (or correlated) with its Total Cash From Operating Activities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Cash From Operating Activities has no effect on the direction of Gross Profit Margin i.e., Integra LifeSciences' Gross Profit Margin and Total Cash From Operating Activities go up and down completely randomly.
Correlation Coefficient | 0.01 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Gross Profit Margin
Total Cash From Operating Activities
Most indicators from Integra LifeSciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Integra LifeSciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Integra LifeSciences' Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 442.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 339.5 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 944.6M | 970.3M | 888.4M | 458.0M | Total Revenue | 1.5B | 1.6B | 1.5B | 1.6B |
Integra LifeSciences fundamental ratios Correlations
Click cells to compare fundamentals
Integra LifeSciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Integra LifeSciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.3B | 3.6B | 3.8B | 3.9B | 3.8B | 4.0B | |
Other Current Liab | 156.2M | 182.1M | 213.1M | 158.8M | 176.3M | 185.1M | |
Total Current Liabilities | 331.3M | 401.0M | 340.0M | 320.9M | 307.0M | 158.9M | |
Total Stockholder Equity | 1.4B | 1.5B | 1.7B | 1.8B | 1.6B | 1.7B | |
Property Plant And Equipment Net | 431.9M | 371.2M | 396.2M | 459.6M | 496.4M | 521.2M | |
Net Debt | 1.3B | 1.2B | 1.1B | 1.2B | 1.4B | 1.5B | |
Retained Earnings | 398.6M | 532.3M | 698.6M | 879.1M | 946.9M | 994.2M | |
Accounts Payable | 113.1M | 54.6M | 61.8M | 102.1M | 92.3M | 96.9M | |
Cash | 198.9M | 470.2M | 513.4M | 456.7M | 276.4M | 290.2M | |
Non Current Assets Total | 2.4B | 2.4B | 2.6B | 2.7B | 2.7B | 2.9B | |
Non Currrent Assets Other | 11.2M | 11.3M | 10.0M | (510.2M) | 26.0M | 27.3M | |
Cash And Short Term Investments | 198.9M | 470.2M | 513.4M | 456.7M | 309.1M | 324.6M | |
Net Receivables | 275.3M | 225.5M | 231.8M | 263.5M | 259.3M | 272.3M | |
Common Stock Shares Outstanding | 86.5M | 85.2M | 85.5M | 83.5M | 80.3M | 67.2M | |
Liabilities And Stockholders Equity | 3.3B | 3.6B | 3.8B | 3.9B | 3.8B | 4.0B | |
Non Current Liabilities Total | 1.6B | 1.7B | 1.8B | 1.8B | 1.9B | 2.0B | |
Inventory | 316.1M | 310.1M | 317.4M | 324.6M | 389.6M | 409.1M | |
Other Current Assets | 67.9M | 231.4M | 91.1M | 116.8M | 100.0M | 51.5M | |
Other Stockholder Equity | 1.1B | 1.1B | 1.0B | 914.1M | 655.2M | 467.2M | |
Total Liab | 1.9B | 2.1B | 2.1B | 2.1B | 2.2B | 2.3B | |
Property Plant And Equipment Gross | 431.9M | 371.2M | 711.1M | 789.3M | 863.8M | 907.0M | |
Total Current Assets | 858.2M | 1.2B | 1.2B | 1.2B | 1.1B | 1.1B | |
Accumulated Other Comprehensive Income | (76.4M) | (74.1M) | (45.2M) | 10.3M | (15.1M) | (15.9M) | |
Intangible Assets | 1.0B | 989.4M | 1.1B | 1.1B | 1.1B | 1.1B | |
Short Long Term Debt Total | 1.5B | 1.7B | 1.7B | 1.6B | 1.7B | 1.8B | |
Common Stock Total Equity | 887K | 893K | 896K | 905K | 1.0M | 528.7K | |
Short Term Investments | 1.5M | 4.7M | 12K | 16.7M | 32.7M | 34.3M | |
Short Term Debt | 57.3M | 159.1M | 59.8M | 52.7M | 29.8M | 28.3M | |
Common Stock | 887K | 893K | 896K | 905K | 909K | 547.5K | |
Other Liab | 116.1M | 131.2M | 135.9M | 201.8M | 232.1M | 243.7M | |
Other Assets | 27.3M | 168.6M | 3.8B | 63.2M | 72.6M | 69.0M | |
Long Term Debt | 1.2B | 1.4B | 1.4B | 1.3B | 1.5B | 749.7M | |
Treasury Stock | (119.9M) | (235.1M) | (234.4M) | (362.9M) | (326.6M) | (310.2M) | |
Property Plant Equipment | 337.4M | 287.5M | 311.7M | 311.3M | 358.0M | 375.9M | |
Current Deferred Revenue | 4.8M | 5.3M | 5.3M | 7.3M | 8.5M | 5.3M | |
Good Will | 954.3M | 932.4M | 1.0B | 1.0B | 1.1B | 1.1B | |
Net Tangible Assets | (569.1M) | (406.9M) | (474.2M) | (361.1M) | (325.0M) | (341.2M) | |
Retained Earnings Total Equity | 398.6M | 532.3M | 698.6M | 879.1M | 1.0B | 1.1B | |
Long Term Debt Total | 1.2B | 1.4B | 1.4B | 1.3B | 1.5B | 1.0B | |
Capital Surpluse | 1.2B | 1.3B | 1.3B | 1.3B | 1.5B | 1.0B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Integra Stock analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
CEOs Directory Screen CEOs from public companies around the world | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Integra LifeSciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Integra LifeSciences. If investors know Integra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Integra LifeSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.60) | Earnings Share 0.84 | Revenue Per Share 19.248 | Quarterly Revenue Growth (0) | Return On Assets 0.0424 |
The market value of Integra LifeSciences is measured differently than its book value, which is the value of Integra that is recorded on the company's balance sheet. Investors also form their own opinion of Integra LifeSciences' value that differs from its market value or its book value, called intrinsic value, which is Integra LifeSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integra LifeSciences' market value can be influenced by many factors that don't directly affect Integra LifeSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integra LifeSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Integra LifeSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integra LifeSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.